Table 2.
HIV-related variables
| Erectile dysfunction | No erectile dysfunction | P | |
|---|---|---|---|
| Months since HIV diagnosis, mean (SD) | 87.4 (64.1) | 102.6 (80.7) | 0.32 |
| CD4 nadir, mean (SD) | 210.5 (189.9) | 190.7 (168.4) | 0.58 |
| Actual CD4, mean (SD) | 421.2 (240.9) | 464.4 (263.7) | 0.40 |
| Viral load, mean (SD) | 4,964.3 (20,807.4) | 225.9 (852.3) | 0.18 |
| Months on HAART, mean (SD) | 55.9 (44.1) | 57.2 (49.8) | 0.90 |
| History of protease inhibitor use, n (%) | |||
| Yes | 28 (39.4) | 17 (39.5) | 0.59 |
| No | 43 (60.6) | 23 (60.5) | |
| Current protease inhibitor use, n (%) | |||
| Yes | 37 (52.1) | 19 (50) | 0.83 |
| No | 34 (47.9) | 19 (50) | |
| Current NNRTI use, n (%) | |||
| Yes | 43 (60.6) | 27 (71.1) | 0.28 |
| No | 28 (39.4) | 11 (28.9) | |
| Current NRTI use, n (%) | |||
| Yes | 46 (64.8) | 27 (71.1) | 0.51 |
| No | 25 (35.2) | 11 (28.9) | |
| Current integrase inhibitor use, n (%) | |||
| Yes | 2 (2.8) | 0 (0) | 0.30 |
| No | 69 (97.2) | 38 (100) |
HIV = human immunodeficiency virus, SD = standard deviation, HAART = highly active antiretroviral therapy, NNRTI = non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside reverse transcriptase inhibitor